LCE2B

Across TCGA pan-cancer cohorts, LCE2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCE2B data layer compared with 15 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LCE2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCE2B expression acts as an unfavorable survival marker.

ACC, LUAD, and UCEC are the cancer types where LCE2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
LUAD	DFS	Median	III,IV	0.206	0.670	.015	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LCE2B–ACC (DFS)

Open the ACC breakdown →